Login to Your Account

Deals Roundup

Maxygen Partners Hemophilia Drug in Potential $120M Deal

By Jennifer Boggs

Thursday, July 3, 2008
Maxygen Inc. landed a big pharma partner for its early stage hemophilia candidate, MAXY-VII, signing a licensing deal with Bayer HealthCare in exchange for $90 million in cash up front and potentially $30 million more in milestones down the road. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription